Bailard Inc. Purchases Shares of 20,000 Sangamo Therapeutics Inc (SGMO)

Bailard Inc. purchased a new stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $380,000.

A number of other institutional investors and hedge funds have also bought and sold shares of SGMO. California State Teachers Retirement System grew its holdings in Sangamo Therapeutics by 5.0% in the 3rd quarter. California State Teachers Retirement System now owns 132,741 shares of the biopharmaceutical company’s stock valued at $1,991,000 after buying an additional 6,360 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Sangamo Therapeutics by 13.6% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 433,717 shares of the biopharmaceutical company’s stock valued at $7,113,000 after buying an additional 51,801 shares during the period. Fox Run Management L.L.C. grew its holdings in Sangamo Therapeutics by 353.8% in the 4th quarter. Fox Run Management L.L.C. now owns 63,075 shares of the biopharmaceutical company’s stock valued at $1,034,000 after buying an additional 49,175 shares during the period. Chicago Equity Partners LLC purchased a new stake in Sangamo Therapeutics in the 4th quarter valued at about $192,000. Finally, American Century Companies Inc. grew its holdings in Sangamo Therapeutics by 36.8% in the 4th quarter. American Century Companies Inc. now owns 469,099 shares of the biopharmaceutical company’s stock valued at $7,693,000 after buying an additional 126,121 shares during the period. Institutional investors own 63.74% of the company’s stock.

Several research firms have commented on SGMO. Zacks Investment Research cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 10th. ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 8th. BidaskClub cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. Wedbush reiterated a “hold” rating and set a $8.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, March 13th. Finally, Barclays reiterated a “buy” rating and set a $30.00 target price on shares of Sangamo Therapeutics in a report on Sunday, February 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $21.67.

Shares of NASDAQ:SGMO opened at $15.70 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.78 and a quick ratio of 4.78. Sangamo Therapeutics Inc has a 1 year low of $15.20 and a 1 year high of $16.00. The stock has a market cap of $1.56 billion, a PE ratio of -22.43 and a beta of 2.83.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.29 by ($0.52). Sangamo Therapeutics had a negative return on equity of 30.96% and a negative net margin of 126.96%. The firm had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $53.09 million. During the same quarter in the previous year, the firm posted ($0.23) EPS. The firm’s revenue for the quarter was up 270.6% compared to the same quarter last year. sell-side analysts forecast that Sangamo Therapeutics Inc will post -0.22 EPS for the current year.

In related news, Director Steven J. Mento sold 9,433 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $23.27, for a total transaction of $219,505.91. Following the transaction, the director now directly owns 8,480 shares of the company’s stock, valued at approximately $197,329.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Saira Ramasastry sold 9,450 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $24.88, for a total value of $235,116.00. Following the transaction, the director now directly owns 9,450 shares in the company, valued at $235,116. The disclosure for this sale can be found here. Insiders have sold a total of 76,539 shares of company stock valued at $1,657,925 in the last quarter. Company insiders own 1.20% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply